ArticleCell journal
Current Biosafety Considerations in Stem Cell Therapy.
Article in Cell journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 42 citations in OpenAlex.
- The regenerative journey: exploring stem cell roles from injury detection to tissue repair.Stem cell research & therapy · 2025Review
- Adipose-derived stem cell exosomes alleviate TGF-β1-induced urethral stricture fibrosis by suppressing the TGF-β/Smad pathway and downstream PDGFR-β/RAS/ERK signaling.Journal of cell communication and signaling · 2025Article
- Preclinical efficacy and safety assessments of Adult human neural stem cells (AhNSCs) for spinal cord injury.Toxicology reports · 2025Article
- Induced Mesenchymal Stem Cells-Small Extracellular Vesicles Alleviate Post-stroke Cognitive Impairment by Rejuvenating Senescence of Neural Stem Cells.Journal of molecular neuroscience : MN · 2024Article
- Regulation of cell fate by cell imprinting approach in vitro.BioImpacts : BI · 2024Review
- Recent advances in the diagnosis and management of acute myocardial infarction.Journal of the Chinese Medical Association : JCMA · 2023Review
- Nano-biomaterials and advanced fabrication techniques for engineering skeletal muscle tissue constructs in regenerative medicine.Nano convergence · 2023Review
- Inflammation and immunomodulation in central nervous system injury - B cells as a novel therapeutic opportunity.Neurobiology of disease · 2023Review
- Mesenchymal stem cell-derived extracellular vesicles/exosome: A promising therapeutic strategy for intracerebral hemorrhage.Regenerative therapy · 2023Review
- Neurogenesis in aging and age-related neurodegenerative diseases.Ageing research reviews · 2022Review
- Harnessing the Therapeutic Potential of Extracellular Vesicles for Biomedical Applications Using Multifunctional Magnetic Nanomaterials.Small (Weinheim an der Bergstrasse, Germany) · 2022Review
- Extracellular Vesicle Application as a Novel Therapeutic Strategy for Ischemic Stroke.Translational stroke research · 2022Review
- High Therapeutic and Esthetic Properties of Extracellular Vesicles Produced from the Stem Cells and Their Spheroids Cultured from Ocular Surgery-Derived Waste Orbicularis Oculi Muscle Tissues.Antioxidants (Basel, Switzerland) · 2021Article
- Therapeutic potential of stem cells from human exfoliated deciduous teeth infusion into patients with type 2 diabetes depends on basal lipid levels and islet function.Stem cells translational medicine · 2021Article
- Effect of Stem Cell-Derived Extracellular Vesicles on Damaged Human Corneal Endothelial Cells.Stem cells international · 2021Article
- Defining a Regulatory Strategy for ATMP/Aerosol Delivery Device Combinations in the Treatment of Respiratory Disease.Pharmaceutics · 2020Review
- Harnessing the Neural Stem Cell Secretome for Regenerative Neuroimmunology.Frontiers in cellular neuroscience · 2020Review
- Non-immunogenic Induced Pluripotent Stem Cells, a Promising Way Forward for Allogenic Transplantations for Neurological Disorders.Frontiers in genome editing · 2020Review
- Untargeted histone profiling during naive conversion uncovers conserved modification markers between mouse and human.Scientific reports · 2019Article
- Potential of Exosomes for the Treatment of Stroke.Cell transplantation · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stem cells can be valuable model systems for drug discovery and modelling human diseases as well as to investigate cellular interactions and molecular events in the early stages of development. Controlling the differentiation of stem cells into specific germ layers provides a potential source of highly specialized cells for therapeutic applications. In recent years, finding individual properties of stem cells such as their ultimate self-renewal capacity and the generation of particular cell lines by differentiation under specific culture conditions underpins the development of regenerative therapies. These futures make stem cells a leading candidate to treat a wide range of diseases. Nevertheless, as with all novel treatments, safety issues are one of the barriers that should be overcome to guarantee the quality of a patient's life after stem cell therapy. Many studies have pointed to a large gap in our knowledge about the therapeutic applications of these cells. This gap clearly shows the importance of biosafety concerns for the current status of cell-based therapies, even more than their therapeutic efficacy. Currently, scientists report that tumorigenicity and immunogenicity are the two most important associated cell-based therapy risks. In principle, intrinsic factors such as cell characteristics and extrinsic elements introduced by manufacturing of stem cells can result in tumor formation and immunological reactions after stem cell transplantation. Therapeutic research shows there are many biological questions regarding safety issues of stem cell clinical applications. Stem cell therapy is a rapidly advancing field that needs to focus more on finding a comprehensive technology for assessing risk. A variety of risk factors (from intrinsic to extrinsic) should be considered for safe clinical stem cell therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.